2025
SJR Q2
JCR Q3 · 2,5
OA
89 eşleşen makale
SCIE
Dergi ayrıntısı
Cancer Chemotherapy and Pharmacology
- Yayıncı
- Springer Science and Business Media Deutschland GmbH
- Ülke
- Germany · Western Europe
- Tür
- journal
- ISSN
-
0344570414320843
Bütünleşik değerlendirme
Scopus tarafı Scimago SJR; WoS tarafı Master Journal List + JCR/JIF. Kaynaklar ISSN üzerinden eşleştirilir. WoS / JCR metrikleri yalnızca 1997 ve sonrası yıllar için vardır.
WoS / JCR verileri 1997 ve sonrası içindir.
Scopus
Scopus · Scimago
- SJR 0,851
- Quartile Q2
- H-Index 132
- Atıf/yayın 2,44
- Doküman (3y) 351
- Atıf (3y) 902
Clarivate
Web of Science · JCR · 2025
- JCR Q Q3
- JIF 2,5
- 5Y JIF 2,7
- JCI 0,58
WoS indeksleri
- SCIE
Konu sınıflandırması
Kategoriler (SJR)
- Cancer Research Q3
- Oncology Q2
- Pharmacology Q2
- Pharmacology (medical) Q2
- Toxicology Q2
Alanlar
- Biochemistry, Genetics and Molecular Biology
- Medicine
- Pharmacology, Toxicology and Pharmaceutics
WoS kategorileri
- Oncology | Pharmacology & Pharmacy
Yıllık quartile karşılaştırması
Scimago (SJR) tüm yıllar; Clarivate (JCR / JIF / JCI) 1997 ve sonrası. Güncel yıl açık; diğer yıllar kapalıdır.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q3 | 0,851 | 2,5 | 2,7 | 0,58 | Q3 | 132 |
| 2024 | Q1 | Q3 | 0,969 | 2,3 | 2,5 | 0,64 | Q3 | 127 |
| 2023 | Q1 | Q2 | 0,869 | 2,7 | 2,7 | 0,7 | Q2 | 127 |
| 2022 | Q1 | Q3 | 0,811 | 3 | 3,1 | 0,7 | Q2 | 127 |
| 2021 | Q1 | Q3 | 0,848 | 3,3 | 3,6 | 0,73 | Q2 | 127 |
| 2020 | Q1 | Q3 | 1,112 | 3,3 | 3,4 | 0,8 | Q2 | 127 |
| 2019 | Q1 | Q2 | 1,239 | 3 | 2,8 | 0,87 | Q2 | 127 |
| 2018 | — | Q2 | — | 3 | 2,8 | 0,88 | Q2 | — |
| 2017 | Q1 | Q2 | 1,147 | 2,8 | 2,9 | 0,91 | Q2 | 127 |
| 2016 | Q1 | Q2 | 1,204 | 2,7 | 2,7 | — | — | 127 |
| 2015 | Q1 | Q2 | 1,266 | 2,8 | 2,7 | — | — | 127 |
| 2014 | Q1 | Q2 | 1,141 | 2,8 | 2,7 | — | — | 127 |
| 2013 | Q1 | Q2 | 1,122 | 2,6 | 2,6 | — | — | 127 |
| 2012 | Q1 | Q2 | 1,081 | 2,8 | 2,8 | — | — | 127 |
| 2011 | Q1 | Q2 | 1,071 | 2,8 | 2,7 | — | — | 127 |
| 2010 | Q1 | Q2 | 1,219 | 2,8 | 2,6 | — | — | 127 |
| 2009 | — | Q2 | — | 2,7 | 2,5 | — | — | — |
| 2008 | — | Q2 | — | 2,7 | 2,5 | — | — | — |
| 2007 | — | Q2 | — | 2,6 | 2,4 | — | — | — |
| 2006 | — | Q2 | — | 2,4 | — | — | — | — |
| 2005 | — | Q2 | — | 2,2 | — | — | — | — |
| 2004 | — | Q2 | — | 2,2 | — | — | — | — |
| 2003 | — | Q2 | — | 2 | — | — | — | — |
| 2002 | — | Q2 | — | 1,9 | — | — | — | — |
| 2001 | — | Q2 | — | 2,2 | — | — | — | — |
| 2000 | — | Q2 | — | 2,1 | — | — | — | — |
| 1999 | — | Q2 | — | 1,7 | — | — | — | — |
| 1998 | — | Q2 | — | 1,7 | — | — | — | — |
| 1997 | — | Q2 | — | 1,2 | — | — | — | — |
JCR kategori quartile geçmişi
Yıla ve kategoriye göre JCR / JCI quartile. 1997 ve sonrası.
WoS / JCR verileri 1997 ve sonrası içindir.
| Yıl | Kategori | Edition | JCR Q (1997+) | JCI Q (1997+) | Sıra |
|---|---|---|---|---|---|
| 2025 | ONCOLOGY | SCIE | Q3 | Q3 | 204/333 |
| 2025 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 205/356 |
| 2024 | ONCOLOGY | SCIE | Q3 | Q3 | 208/328 |
| 2024 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q3 | 202/352 |
| 2023 | ONCOLOGY | SCIE | Q3 | Q2 | 163/322 |
| 2023 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 167/354 |
| 2022 | ONCOLOGY | SCIE | Q3 | Q2 | 157/241 |
| 2022 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 157/278 |
| 2021 | ONCOLOGY | SCIE | Q3 | Q2 | 168/245 |
| 2021 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 160/279 |
| 2020 | ONCOLOGY | SCIE | Q3 | Q2 | 166/242 |
| 2020 | PHARMACOLOGY & PHARMACY | SCIE | Q3 | Q2 | 147/276 |
| 2019 | ONCOLOGY | SCIE | Q3 | Q2 | 139/244 |
| 2019 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 113/271 |
| 2018 | ONCOLOGY | SCIE | Q3 | Q2 | 117/230 |
| 2018 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 101/267 |
| 2017 | ONCOLOGY | SCIE | Q3 | Q2 | 133/223 |
| 2017 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | Q2 | 107/261 |
| 2016 | ONCOLOGY | SCIE | Q3 | — | 122/217 |
| 2016 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 112/257 |
| 2015 | ONCOLOGY | SCIE | Q3 | — | 111/213 |
| 2015 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 89/255 |
| 2014 | ONCOLOGY | SCIE | Q3 | — | 110/211 |
| 2014 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 98/255 |
| 2013 | ONCOLOGY | SCIE | Q3 | — | 112/203 |
| 2013 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 107/256 |
| 2012 | ONCOLOGY | SCIE | Q2 | — | 89/197 |
| 2012 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 89/261 |
| 2011 | ONCOLOGY | SCIE | Q2 | — | 84/196 |
| 2011 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 92/261 |
| 2010 | ONCOLOGY | SCIE | Q2 | — | 84/185 |
| 2010 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 89/252 |
| 2009 | ONCOLOGY | SCIE | Q2 | — | 76/166 |
| 2009 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 96/237 |
| 2008 | ONCOLOGY | SCIE | Q2 | — | 69/143 |
| 2008 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 81/219 |
| 2007 | ONCOLOGY | SCIE | Q2 | — | 66/132 |
| 2007 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 74/205 |
| 2006 | ONCOLOGY | SCIE | Q3 | — | 66/127 |
| 2006 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 82/199 |
| 2005 | ONCOLOGY | SCIE | Q3 | — | 68/123 |
| 2005 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 75/193 |
| 2004 | ONCOLOGY | SCIE | Q3 | — | 63/123 |
| 2004 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 65/187 |
| 2003 | ONCOLOGY | SCIE | Q3 | — | 65/120 |
| 2003 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 71/185 |
| 2002 | ONCOLOGY | SCIE | Q3 | — | 58/114 |
| 2002 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 68/188 |
| 2001 | ONCOLOGY | SCIE | Q2 | — | 47/107 |
| 2001 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 48/186 |
| 2000 | ONCOLOGY | SCIE | Q2 | — | 38/103 |
| 2000 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 49/181 |
| 1999 | ONCOLOGY | SCIE | Q2 | — | 47/105 |
| 1999 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 60/175 |
| 1998 | ONCOLOGY | SCIE | Q2 | — | 44/104 |
| 1998 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 46/178 |
| 1997 | ONCOLOGY | SCIE | Q2 | — | 51/102 |
| 1997 | PHARMACOLOGY & PHARMACY | SCIE | Q2 | — | 77/157 |